H3K4me3重塑诱导通过O-GlcNAc转移酶获得的耐药性
Dinoop Ravindran Menon1, Heinz Hammerlindl2, Gregory Gimenez3
1Frazer Institute, The University of Queensland, Brisbane, QLD, Australia; Department of Dermatology, University of Colorado Denver, Aurora, CO, USA; Department of Medical Oncology, University of Colorado Denver, Aurora, CO, USA.
通过O相关的N-乙糖胺转移酶 (OGT) 改造的素H3 lysine-4三甲基化 (H3K4me3) 驱动癌症的适应性耐药性. 抑制OGT或其上游激活剂AMPK延迟了获得的抵抗,提供了新的治疗策略.
科学领域:
- 癌症生物学 癌症生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 药物耐药性机制 药物耐药性机制
背景情况:
- 癌症中耐药增殖性持续性 (DTPP) 状态的理解很少.
- 希斯H3 lysine-4三甲基化 (H3K4me3) 可能有助于药物耐受性持久性 (DTPs) 的恢复.
研究的目的:
- 识别用H3K4me3.3标记的转录活性位点.
- 揭示DTPP状态和适应性耐药性的关键调节者.
主要方法:
- 在癌症药物耐受性模型中利用了H3K4me3 ChIP-Seq.
- 鉴定了转录因子的结合动机,并研究了O-链接的N-乙糖胺转移酶 (OGT) 的参与.
- 进行了代谢学,生化分析和体外/体内实验,以评估OGT的作用.
主要成果:
- H3K4me3重塑发生在与O-GlcNAc.相关的CpG岛屿地区.
- 在接受治疗的癌细胞中观察到OGT,O-GlcNAc和TET1的升级.
- 抑制OGT降低了H3K4me3,降低了抗性基因的调节,并防止了体内获得的抗性.
- 以AMP激活的蛋白激酶 (AMPK) 被确定为上游目标;它的激活延迟了耐药性.
结论:
- 发现了一种涉及癌细胞重编程的适应性耐药性机制.
- 这个由OGT和H3K4me3调节的过程可以被向改善治疗持续时间和患者的结果.
更多相关视频
09:40Quantitation and Analysis of the Formation of HO-Endonuclease Stimulated Chromosomal Translocations by Single-Strand Annealing in Saccharomyces cerevisiae
Published on: September 23, 2011
09:42Immunostaining for DNA Modifications: Computational Analysis of Confocal Images
Published on: September 7, 2017
相关概念视频
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Nucleosome Remodeling
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
Spreading of Chromatin Modifications
Writers
The writer...
Crossing Over
Somatic to iPS Cell Reprogramming
